I-China yeSigaba soMhlaza wesibindi 4 Unyango ngo-2026: Amachiza amatsha kunye namazinga okusinda - Iindleko 

Inqanaba lesi-4 lomhlaza wesibindi, ekwaziwa ngokuba yi-metastatic hepatocellular carcinoma, imele eyona ndlela iphambili yesifo apho umhlaza usasazeke kumalungu akude okanye i-lymph nodes. Ngo-2026, iiprothokholi zonyango e-China ziye zavela ngokubonakalayo, zisuka kukhathalelo olulula ukuya kunyango olunobundlongondlongo oludibanisa i-immunotherapy, ii-arhente ekujoliswe kuzo, kunye nonyango olutsha lweselula. Idatha yangoku ibonisa ukuba amazinga aphakathi okusinda kwizigulane zenqanaba lesi-4 e-China aye anda ukusuka kwi-avareji yembali engaphantsi kweenyanga ezili-12 ukuya malunga neenyanga ezili-18-24, kunye nabanye abasindileyo bexesha elide abadlula iminyaka emihlanu ngenxa yokuvunywa kwamachiza amatsha kunye nokufikelela kulingo lwezonyango.

Ukuqonda iSigaba se-4 soMhlaza weSibindi kwi-2026 Landscape

Inqanaba lesi-4 lomhlaza wesibindi libonakaliswa ngokusasazeka kweeseli ezinobungozi ngaphaya kwesibindi ukuya kwamanye amalungu omzimba, njengemiphunga, amathambo, okanye i-lymph nodes ezikude. Ngokwembali, olu xilongo luthwele uqikelelo olubi olunokhetho olulinganiselweyo lonyango. Nangona kunjalo, imeko yezonyango ngo-2026 itshintshe kakhulu, ngakumbi kwicandelo le-oncology laseTshayina.

Inkcazo yenqanaba lesi-4 ihleli ingaguquguquki kwihlabathi jikelele, kodwa indlela yokulawula e-China ngoku ixhasa indibaniselwano eyodwa yamachiza aphuhliswe ekhaya kunye nemigangatho eyaziwayo kumazwe ngamazwe. Ugxininiso luye lwatshintshela "kunyango lokuguqulwa," apho injongo ikukunciphisa amathumba ngokwaneleyo ukwenzela ukuba iimeko ezingasebenzi ngaphambili zifanelekele ukuchithwa kotyando okanye ukukhutshwa kwendawo.

Izigulane ezifunyanwe kweli nqanaba zihlala zibonisa iimpawu ezibalulekileyo, kuquka i-jaundice, i-ascites, ukudinwa okukhulu, kunye neentlungu. Nangona le mingeni, ukuhlanganiswa kwamaqela amacandelo amaninzi (MDT) kwizibhedlele eziphezulu zaseTshayina ziqinisekisa ukuba isigulane ngasinye sifumana uvavanyo lomntu. Le ndlela yokujongana nayo yonke into ayijongi umthwalo wethumba kuphela kodwa nomsebenzi wesibindi osisiseko, obaluleke kakhulu kubemi abanamazinga aphezulu eHepatitis B.

Iimpawu eziphambili zeSigaba sesi-4 soFundo

• I-Metastasis ekude: Iiseli zomhlaza ziye zahamba ngegazi okanye inkqubo ye-lymphatic ukuya kumalungu angaphandle kwesibindi.
• Uhlaselo lweVascular: Uhlaselo olukhulu lwemithambo yegazi emikhulu njenge-portal vein okanye i-hepatic vein luxhaphakile.
• Ukuthotywa kokusebenza kwesibindi: Izigulana ezininzi zinengxaki ye-cirrhosis okanye i-hepatitis engapheliyo, nto leyo eyenza kube nzima ukunyamezela unyango.
• Umthwalo oneempawu: Amathuba aphezulu okuba neentlungu, ukwehla kobunzima, kunye nokuqokelelwa kolwelo olufuna ukhathalelo lwenkxaso ecaleni konyango oluchasene nomhlaza.

Ukuvunywa kweChiza okutsha kunye noNyango oluPhumeleleyo e-China ngo-2026

Unyaka wama-2026 uphawula umzuzu obalulekileyo wonyango lomhlaza wesibindi e-China, eqhutywa kukwamkelwa kwee-arhente zenoveli ezininzi kunye nokuphuculwa kweerejimeni ezidityanisiweyo ezikhoyo. Ulawulo lweeMveliso zoNyango lweSizwe (i-NMPA) lukhawulezise inkqubo yokuvunywa kwamachiza ajolise kwiindlela ezithile zeemolekyuli, enika ithemba elitsha kwizigulane zesigaba sesi-4.

Eyona nto ibalulekileyo kukwamkelwa ngokubanzi kwezicwangciso ze-“Target plus Immune” (T+I). Ezi ndibaniselwano zidibanisa i-tyrosine kinase inhibitors (TKIs) kunye ne-immune checkpoint inhibitors (ICIs) ukuthintela kwangaxeshanye imiqondiso yokukhula kwethumba kwaye kusebenze amajoni omzimba wesigulana ukuba ahlasele iiseli zomhlaza. Le ndlela yenkqubo-mbini iye yaba ngumgangatho omtsha wokhathalelo lonyango lodidi lokuqala.

Ngaphaya koko, i-China ibone ukunyuka kweebhayoloji eziphuhliswe ekhaya ezibonelela ngokusebenza ngokulinganayo kwiibrendi zehlabathi kodwa ngexabiso elifikelelekayo. Ezi zintlupheko zasekhaya zihlaziya kwakhona i-algorithm yonyango, inika ezinye iindlela kwizigulane ezinokuthi zingayinyamezeli imigangatho yamazwe ngamazwe okanye ziqhubele phambili kuzo.

I-Lenvatinib Idibaniswe ne-TACE kunye ne-Immunotherapy

Enye yezona nkqubela zibalulekileyo ngo-2025 kunye nokuqhubekeka ngo-2026 kukuvunywa ngokusemthethweni kweLenvatinib ngokudityaniswa nePembrolizumab kunye neTransarterial Chemoembolization (TACE). Le ndlela yokusongela kathathu, iqinisekiswe luphononongo lwe-LEAP-012, imele ihlabathi lokuqala ekuhlanganiseni i-radiology yongenelelo kunye nenkqubo ekujoliswe kuyo kunye nonyango lwe-immune.

Le regimen yenzelwe ngokukodwa i-non-metastatic hepatocellular carcinoma, kodwa imigaqo yayo isetyenziswa ngakumbi kwisigaba se-oligometastatic kwiimeko ze-4 ukulawula isifo se-intrahepatic ngelixa ulawula ukusasazeka okude. Idatha ibonisa izinga lokusinda leenyanga ezingama-24 lilonke le-75%, ukuphucuka okukhulu kuneebenchmarks zangaphambili.

Indlela yokusebenza ibandakanya i-TACE yokuqhawula unikezelo lwegazi kwithumba lesibindi, iLenvatinib inhibiting angiogenesis ukumisa ukwakheka komthambo omtsha wegazi, kunye nePembrolizumab ekhulula ii-T-seli ukucima iiseli zomhlaza ezishiyekileyo. Le mpembelelo ye-synergistic ibangele ukusinda kwe-median-free-free-free yeenyanga ze-14.6 kwizilingo zeklinikhi.

IFinotonlimab: Indlu entsha yaMandla yasekhaya

I-Finotonlimab, ephuhliswe nguSinocelltech, yavela njengomtshintshi-mdlalo ekuqaleni kwe-2025 kwaye ngoku isisiseko sonyango lwe-4 e-China. Ivunywe ngoFebruwari 2025 ngenxa yokunganyangeki okanye i-metastatic hepatocellular carcinoma, le PD-1 inhibitor isetyenziswa ngokuqhelekileyo ngokudibanisa ne-bevacizumab biosimilar.

Idatha yeklinikhi ibonisa izinga lempendulo yenjongo (ORR) ye-33%, iphezulu kakhulu kune-4% ebonwa kumaqela olawulo afumana ukunakekelwa okusemgangathweni yedwa. Okubaluleke ngakumbi, ukusinda okupheleleyo okuphakathi kwafikelela kwiinyanga ze-22.1, ukunciphisa umngcipheko wokufa nge-40% xa kuthelekiswa nengalo yokulawula.

Ukufikeleleka kwe-Finotonlimab kuye kwandiswa ngokubandakanywa kwayo kwizikim ze-inshorensi yesizwe kumaphondo amaninzi, nto leyo eyenza ukuba olu nyango lufikelelekayo lufikeleleke kubantu ngokubanzi. Iprofayili yayo yokhuseleko iyathandeka, ineziphumo ebezingalindelekanga ezilawulekayo ezivumela izigulane ukuba zigcine umgangatho wobomi obungcono ngexesha lonyango.

I-"O + Y" ye-Dual Immunotherapy Regimen

Indibaniselwano ye-Nivolumab kunye ne-Ipilimumab, edla ngokubizwa ngokuba yi-"O+Y" irejimeni, ifumene imvume e-China ngo-Matshi 2025 yonyango lokuqala lwe-hepatocellular carcinoma. Olu thintelo lwe-double-checkpoint blockade ijolise kuzo zombini iindlela ze-PD-1 kunye ne-CTLA-4, enikezela ngesicwangciso esinamandla sokuvuselela i-immune.

Le ndlela iluncedo kakhulu kwizigulana ezinomthwalo omkhulu wethumba okanye abo baye basilela kwi-TKI monotherapies yangaphambili. Ukuqina kokuphendula nge "O + Y" kuyaphawuleka, kunye ne-subset yezigulane ezifumana ukusinda kwexesha elide ngaphaya kweminyaka emithathu, ukunqabile kwinqanaba le-4 lomhlaza wesibindi ngokwembali.

Ngelixa iprofayili yetyhefu inokuba phezulu ngenxa yeziganeko ezimbi ezinxulumene nomzimba wokuzikhusela, ukulawulwa ngononophelo ziingcali ze-oncologists ezinamava kuvumela uninzi lwezigulana ukuba zithole inzuzo enkulu. Irejimeni ngoku ifumaneka ngokubanzi kwizibhedlele ezikumgangatho omnye kuzo zonke izixeko ezikhulu zaseTshayina njengeBeijing, iShanghai, neGuangzhou.

Amazinga okusinda kunye noHlaziyo lwePrognosis ngo-2026

Ukuqonda amanani-nkcazo okusinda kubalulekile kwizigulana kunye neentsapho ezihamba kwinqanaba lesi-4 lokuxilongwa. Ngelixa idatha yembali izoba umfanekiso ongemfiliba, ukudityaniswa konyango lwangoku ngo-2026 kuyibhale kwakhona ibali. Ukusinda akusalinganiswa nje ngeenyanga kodwa kuyanda ngeminyaka kwizigulane ezisabelayo.

Kubalulekile ukwahlula phakathi kokusinda okuphakathi kunye namazinga okusinda kwexesha elide. Ukusinda kweMedi kubonisa indawo ephakathi apho isiqingatha sezigulane siphila ixesha elide kwaye isiqingatha siphila mfutshane. Nangona kunjalo, "umsila" wegophe lokusinda uyakhula, oku kuthetha ukuba izigulane ezininzi ziba ngabasindi bexesha elide.

Izinto eziphembelela ezi zilinganiso ziquka ubungakanani be-metastasis, ukugcinwa kwesibindi (inqaku lomntwana-Pugh), isimo sokusebenza, kunye nokuphendula kunyango lokuqala. Izigulana ezinomsebenzi wesibindi ohlawulelwe kakuhle kunye nokusasazeka kwe-metastatic okulinganiselweyo kudla ngokuba ngcono kakhulu.

Iinkcukacha-manani zangoku zokuSinda

• Ukusinda ngokupheleleyo kweMedi: Ngonyango lwangoku lodidi lokuqala oludityanisiweyo (TKI + ICI), ubomi obuphakathi ngoku busuka kwi-18 ukuya kwiinyanga ezingama-24, ukonyuka okuphawulweyo ukusuka kwiinyanga ezili-10-13 ezibonwa nge-sorafenib endala ye-monotherapy.
• Umyinge weminyaka emibini yokusinda: Malunga ne-40-50% yezigulane ezinyangwa ngeerejimeni zangoku ziphila ngaphaya kweminyaka emibini, xa kuthelekiswa malunga nama-25% kwiminyaka elishumi edlulileyo.
• Iminyaka Emihlanu Yokusinda: Ngelixa kusengumceli mngeni, ipesenti encinci kodwa ekhulayo yezigulane zenqanaba lesi-4 (eqikelelwa kwi-10-15% kubaviwa abagqwesileyo) bafikelela kumanqaku eminyaka emihlanu, ukunyanga isifo njengesifo esingapheliyo.
• Impembelelo yoTyando lokuGuqulwa: Izigulana ezisabela kakuhle kunyango lwenkqubo kwaye zenziwa uqhaqho loguqulo oluyimpumelelo zibona amazinga azo okusinda kwiminyaka emihlanu etsibela phantse ukuya kuma-50-60%, zilinganisa iziphumo zenqanaba lokuqala.

Izinto Eziphembelela I-Prognosis Yomntu Ngamnye

Uhambo lwesigulane ngasinye lukhethekile. Ubukho bentsholongwane ye-Hepatitis B (HBV) bufuna ulawulo olungqongqo lwe-antiviral ukuthintela ukuphinda kusebenze ngexesha lonyango lwe-immunotherapy, olunokuthi luphazamise ukusebenza kwesibindi. Ngokuchaseneyo, ucinezelo olusebenzayo lwe-HBV lunokuphucula iziphumo zizonke.

Indawo yeemetastases nayo idlala indima. I-Bone metastases inokufuna ukusasazeka kwemitha yolawulo lweentlungu, ngelixa i-metastases emiphungeni inokuba luncedo kunyango lwendawo ukuba ithumba eliphambili lesibindi liyalawulwa. Izigulane ezinesimo esihle sokusebenza (i-ECOG 0-1) zinyamezela ukudibanisa okunamandla ngakumbi kwaye ngaloo ndlela kuzuze iziphumo eziphezulu zokusinda.

Ukubeka iliso rhoqo kunye nokufunyaniswa kwangaphambili kokuqhubela phambili kuvumela ukutshintshela kwangexesha kunyango lodidi lwesibini, ukwandisa ukusinda. Ukufumaneka kwemigca emininzi yonyango olusebenzayo ngo-2026 kuthetha ukuba ukuxilongwa kwesigaba sesi-4 akusiyo isiphelo senyathelo elinye kodwa uhambo olulawulekayo kunye neendlela ezininzi zokungenelela.

Uhlalutyo lweendleko kunye ne-Inshurensi ye-Inshurensi e-China

Inkalo yezemali yonyango lomhlaza yinkxalabo enkulu kwizigulane. Ngo-2026, ixabiso leendleko zonyango lomhlaza wesibindi e-China liye laphucuka ngenxa yamanyathelo karhulumente, ukuthenga okusekelwe kumthamo (VBP), kunye ne-inshurensi eyandisiweyo. Nangona kunjalo, iindleko zisenokwahluka kakhulu ngokuxhomekeke kwirejimeni ekhethiweyo kunye nenqanaba lesibhedlele.

Ngokubanzi, amayeza asekhaya afikeleleka kakhulu kunalawo avela kumazwe angaphandle, kwaye uninzi lweendlela zonyango ezitsha kuxoxiwe ngalo kuLuhlu lweZiyobisi lwembuyekezo yeSizwe (NRDL). Oku kubandakanywa kunciphisa kakhulu iindleko eziphuma epokothweni kwizigulana ezikhuselweyo, okwenza ukhathalelo oluphezulu lufikeleleke kudidi oluphakathi.

Kubantu abangakhuselwanga okanye abo bafuna iindlela zonyango zovavanyo ezingabuyiselwayo, iindleko zihlala zininzi. Kubalulekile ukuba izigulana zixoxe ngetyhefu yezemali kunye nababoneleli bezempilo ukuze bafumane ulungelelwaniso phakathi kokusebenza kakuhle kunye nokufikeleleka.

Iindleko zonyango eziqikelelweyo (Ngonyaka)

Qaphela: Iindleko ziqikelelwa kwaye zixhomekeke kutshintsho ngokusekelwe kumaxabiso esibhedlele, imigaqo-nkqubo yengingqi, kunye neemfuno zedosi ethile. Ukufakwa kwamachiza kwi-NRDL kudla ngokukhokelela ekuthotyweni kwamaxabiso ukuya kutsho kuma-60-70% xa kuthelekiswa noluhlu lwamaxabiso.

Ukuhamba nge-Inshurensi kunye neeNkqubo zoNcedo

Uninzi lwabasebenzi basezidolophini kunye nabahlali be-inshurensi yezonyango e-China ngoku bagubungela umgangatho wokuqala wokhathalelo lomhlaza wesibindi. Izigulane kufuneka ziqinisekise iinkcukacha zabo zomgaqo-nkqubo kunye namaziko asekuhlaleni okhuseleko loluntu. Ukongezelela, iinkampani zamachiza zihlala zibonelela ngeeNkqubo zoNcedo lweSigulana (PAPs) ezibonelela ngeedosi zasimahla emva kwenani elithile lokuthenga okuhlawulweyo.

Kwabo bajongene nobunzima bezemali, iziseko zesisa kunye neengxowa-mali zoncedo ezingqamene nezibhedlele zinokubonelela ngenkxaso eyongezelelweyo. Ukuhamba kwezi zixhobo kudla ngokufuna uncedo lukanontlalontle esibhedlele okanye umphathi wetyala ozinikeleyo, inkonzo exhaphake kakhulu kumaziko amakhulu e-oncology.

Ubuchwephesha obutsha: I-CAR-T kunye noNyango lweSelula

Ngaphandle kwamachiza esintu, i-2026 ibona i-China ikhokela intlawulo kwi-cellular immunotherapies yamathumba aqinileyo, ngakumbi umhlaza wesibindi. I-Chimeric Antigen Receptor T-cell (CAR-T) unyango, kanye kuphela kwi-cancer yegazi, ibonisa isithembiso esiphawulekayo kwi-hepatocellular carcinoma ngokusebenzisa izilingo zonyango.

Eyona nto iphambili ekujoliswe kuyo kwezi zonyango kumhlaza wesibindi yi-Glypican-3 (GPC3), i-antigen echazwe kakhulu kwiiseli zomhlaza wesibindi kodwa ingekho kwizicubu ezininzi eziqhelekileyo. Oku kucacisiwe kunciphisa ubutyhefu obujoliswe kuyo, inkxalabo eqhelekileyo kuphuhliso oluqinileyo lwe-CAR-T tumor.

Iifemu ezininzi zaseTshayina zebhayoloji kunye namaziko emfundo aphehlelele ulingo lwamaziko amaninzi avavanya iiseli ze-CAR-T ekujoliswe kuzo kwi-GPC3. Idatha yangaphambili icebisa ukuba i-subset yenqanaba lesi-4 lonyango lwangaphambili lifumana iimpendulo ezipheleleyo ezihlala ixesha elide, kunye nezinye ezisele zingenamhlaza iminyaka eliqela.

I-Ori-C101: Umgqatswa we-CAR-T wasekhaya othembisayo

I-Ori-C101 ngumgqatswa obalaseleyo kule ndawo, eyilelwe ukoyisa i-immunosuppressive tumor microenvironment yomhlaza wesibindi. Ngokubandakanya imimandla yomqondiso ekhethekileyo, olu nyango luphucula ukuzingisa kunye nokwandiswa kweeseli ze-CAR-T ngaphakathi kwendawo ye-tumor.

Kwizilingo zesigaba sokuqala ezibandakanya izigulane ezingaphumelelanga kwiindlela ezininzi zonyango lwenkqubo, i-Ori-C101 ibonise izinga lokulawula isifo se-90%. Okumangalisayo kukuba, abanye abathathi-nxaxheba bafumene iimpendulo ezingaphelelanga ezithathe iminyaka emibini, kwaye ukusinda kukonke kusondele iminyaka emithathu kubemi abaneziphumo ezibi ngokwembali.

Ulawulo lwe-Ori-C101 lubandakanya ukufakwa okukodwa nge-hepatic artery, ukuhambisa iiseli ezilungisiweyo ngqo kwisibindi. Le ndlela yokuhanjiswa kwendawo yongeza ukuvezwa kwethumba ngelixa kunokunciphisa iziphumo ezibi zenkqubo efana ne-cytokine release syndrome.

Abasindi bexesha elide kwiiMvavanyo ze-CAR-T

Izifundo ezipapashiweyo kwiminyaka yakutshanje ziqaqambisa amandla enguqu kolu nyango. Kukho iimeko ezibhaliweyo zenqanaba le-4 izigulane ezinokuhlaselwa kwe-vascular kunye ne-metastases ezikude eziye zafumana ukuxolelwa okupheleleyo emva kwe-GPC3 unyango lwe-CAR-T. Ezi zigulana ziye zahlala zingenaso isifo ngaphezu kweminyaka esixhenxe ukuya kwesibhozo, zinyangekile kwisifo sabo esibuhlungu.

Ngelixa ubukhulu becala isavalelwe kulingo lwezonyango, ufikelelo kolu nyango luyanda. Amaziko amakhulu omhlaza eBeijing, eShanghai, naseTianjin athatha ngokukhutheleyo abaguli kwizifundo zeSigaba sesi-II nese-III. Kwinqanaba lesi-4 izigulane ezinokhetho olulinganiselweyo, ukubhaliswa kulingo olunjalo kubonisa indlela esebenzayo kunye nenokuthi isindise ubomi.

Ukuthelekiswa koBuchule boNyango

Ukukhetha isicwangciso esifanelekileyo sonyango kwisigaba sesi-4 somhlaza wesibindi kubandakanya ukulinganisa ukusebenza, iziphumo ebezingalindelekanga, iindleko, kunye nezinto ezithile kwisigulane. Olu thelekiso lulandelayo luchaza iindlela eziphambili ezikhoyo eTshayina ngo-2026.

Ukwenza Ukhetho Olufanelekileyo

Inkqubo yokwenziwa kwezigqibo kufuneka isoloko ibandakanya iqela lezinto ezininzi. Izinto ezinjengobukho be-esophageal varices (eyonyusa ingozi yokopha nge-bevacizumab) okanye izifo ezizimelayo (ezinokuthi zichase i-immunotherapy) kufuneka zihlolwe ngononophelo.

Kwizigulane ezine-Hepatitis B, ukuqinisekisa ukunyanzeliswa kwentsholongwane yinto efunekayo ngaphambi kokuqala naluphi na unyango lwe-immunosuppressive okanye i-immune-modulating therapy. Ukungaphumeleli ukwenza oko kunokukhokelela ekungaphumeleli kwesibindi esibulalayo. Ke ngoko, olona nyango "lulungileyo" lolo lulungiselelwe iprofayili yebhayoloji kunye neklinikhi yomntu.

Amanyathelo asebenzayo kwizigulana ezifuna unyango eTshayina

Ukuhamba ngenkqubo yokhathalelo lwempilo eTshayina kwinqanaba lesi-4 lonyango lomhlaza wesibindi kufuna ukulungiswa kunye nolwazi. Ukusuka ekukhetheni isibhedlele esifanelekileyo ukuqonda inkqubo yokubhalisa kwiimvavanyo zeklinikhi, nantsi isikhokelo sesinyathelo ngesinyathelo.

• Inyathelo 1: Qokelela iiRekhodi zonyango: Hlanganisa zonke ii-imaging scans (CT, MRI), iingxelo ze-pathology, kunye neembali zonyango zangaphambili. Iikopi zedijithali zibalulekile kuthethwano olukude.
• Inyathelo lesi-2: Khetha iZiko eliKhethekileyo: Beka phambili izibhedlele ezinamasebe azinikeleyo omhlaza wesibindi kunye namaqela e-MDT. Amaziko aphezulu aquka iFudan University Shanghai Cancer Centre, isibhedlele saseZhongshan, kunye nesibhedlele sasePeking Union Medical College.
• Inyathelo lesi-3: Uthethwano kunye nenqanaba: Cwangcisa idinga lokuphonononga kwakhona olubanzi. Ukulinganisa okuchanekileyo kumisela ukufaneleka kunyango oluthile kunye nezilingo zeklinikhi.
• Inyathelo lesi-4: Xoxa ngoKhetho lwezeMali: Ukunxibelelana nabacebisi bezemali besibhedlele ukuqonda ukhuseleko lwe-inshurensi, uqikelelo oluphuma epokothweni, kunye nokufumaneka kweenkqubo zoncedo.
• Inyathelo lesi-5: Phonononga iiMvavanyo zonyango: Buza i-oncologist malunga nolingo oluqhubekayo lwe-CAR-T, TCR-T, okanye indibaniselwano yamachiza amatsha. Iiwebhusayithi ezifana neChinadrugtrials.org zinokukhangelwa kwizifundo ezivulekileyo.
• Inyathelo lesi-6: Qalisa ngoNyango kunye nokuBeka iliso: Sakuba kuvunyelwene ngesicwangciso, bambelela ngokungqongqo kwishedyuli. Ukulandelela rhoqo kubalulekile ukujonga impendulo kunye nokulawula iziphumo ebezingalindelekanga ngokukhawuleza.

Indima Yezimvo Zesibini

Ngenxa yobunzima benqanaba lesi-4 lomhlaza wesibindi, ukufuna uluvo lwesibini kucetyiswa kakhulu. Iingcali ezohlukeneyo zinokunika iimbono ezahlukeneyo malunga nokuba nokwenzeka kotyando loguqulo okanye ukufaneleka kwendibaniselwano yamachiza athile. Izibhedlele ezininzi eziphezulu e-China zibonelela ngeenkonzo zoluvo lwesibini ezikude, ziququzelela ukufikelela kwizigulana ezisuka kwimimandla ekude.

Ukulawula iZiphumo eziPhakamileyo kunye noMgangatho woBomi

Unyango oluqatha lwenqanaba lesi-4 lomhlaza wesibindi luza neziphumo ebezingalindelekanga ezininzi. Ukulawula oku ngokufanelekileyo kubaluleke kakhulu ekugcineni umgangatho wobomi kunye nokuqinisekisa ukuqhubeka konyango. Imiba eqhelekileyo ibandakanya ukukhathala, ukusabela kwesikhumba sonyawo lwesandla, uxinzelelo lwegazi, isifo sohudo, kunye neziganeko ezimbi ezinxulumene nomzimba.

Ulawulo olusebenzayo lubandakanya ukubeka iliso rhoqo uxinzelelo lwegazi, iimvavanyo zesibindi, kunye nokusebenza kwe-thyroid. Ukunyamekela kwesikhumba kwi-hand-foot syndrome kunye nohlengahlengiso lokutya kwiimpawu zesisu kunokunciphisa kakhulu ukungonwabi.

Ukhathalelo lwePalliative akufanele lujongwe njengokhathalelo lokuphela kobomi kodwa njengenxalenye yohambo lonyango ukusuka kusuku lokuqala. Ukudibanisa ulawulo lweentlungu, inkxaso yesondlo, kunye nokucebisa ngengqondo kunceda izigulane zijongane nokuxhatshazwa ngokomzimba nangokweemvakalelo kwesi sifo.

Iimpembelelo eziPhakamileyo kunye noLawulo

• Ukudinwa: Lawula ngokuzilolonga okusemgangathweni, iindlela zokonga amandla, kunye nokulawula i-anemia okanye ukungasebenzi kakuhle kwedlala lengqula.
• Uxinzelelo lwegazi: Okuqhelekileyo kunye ne-TKIs; ifuna ukujongwa rhoqo kunye nohlengahlengiso lwamayeza e-antihypertensive.
• Izehlo eziChasene noKhuseleko lwamajoni omzimba: Inokuchaphazela naliphi na ilungu; ukuqondwa kwangaphambili kunye nokungenelela kwe-steroid kubalulekile ukunqanda umonakalo omkhulu.
• Umngcipheko Wokopha: Idityaniswe neziyobisi ezichasene ne-angiogenic; ukujongwa kwezahluko phambi kokuba ukuqaliswa kunyanzelekile.

Umbono wexesha elizayo kunye neeNdlela ezisakhulayo

Ikamva lenqanaba lesi-4 lonyango lomhlaza wesibindi eTshayina lijongeka lithembisa. Uphando lusiya ekujoliseni okuchane ngakumbi, ukudibanisa iindlela ezininzi, kunye nonyango lomntu olusekwe kwiprofayili yemfuzo. Impumelelo yokwenziwa kwezinto zasekhaya icebisa ukuba iChina iya kuqhubeka ukuba liziko lophando lomhlaza wesibindi.

Imikhwa ekhulayo iquka ukusetyenziswa kobukrelekrele bokwenziwa ukuqikelela impendulo yonyango, uphuhliso lwezilwa-buhlungu ezibizwa ngokuba zii-bispecific antibodies, kunye nokucocwa konyango lweselula ukujolisa kwii-antigens ezininzi ngaxeshanye. Ezi nkqubela-phambili zijolise ekuguquleni inqanaba lesi-4 lomhlaza wesibindi ekubeni sisifo esilawulekayo esilawulekayo kwinxalenye enkulu yezigulane.

Njengoko idatha ikhula kwaye izigulane ezininzi zixhamla kwezi rejimeni zintsha, i-curves yokusinda iya kuqhubeka nokunyuka ukuya phezulu. Intsebenziswano phakathi kwezifundiswa, ishishini, kunye norhulumente waseTshayina idala inkqubo yendalo eyomeleleyo ukuze kuguqulelwe ngokukhawuleza okufunyaniswe yinzululwazi kuqheliselo lwezonyango.

Isithembiso seyeza lomntu siqu

Ulandelelwano lwe-Genomic lwezicubu ze-tumor luba yinto eqhelekileyo, evumela oogqirha ukuba bachonge utshintsho oluthile olunokuthi luphendule kunyango olujoliswe kuyo. Le ndlela yonyango echanekileyo iqinisekisa ukuba izigulana zifumana olona nyango lusebenzayo kwibhayoloji yethumba, ukunciphisa ubuthi obungeyomfuneko.

Ngaphaya koko, i-biopsies yolwelo (uvavanyo lwegazi olufumanisa ukujikeleza kwe-tumor DNA) iphononongwa njengezixhobo zokubhaqa kwangethuba ukuphindaphinda kunye nokubeka iliso ngexesha lokwenyani lokuphumelela konyango. Le ndlela ingangeneleli inokuguqula indlela elawulwa ngayo umhlaza wesibindi wenqanaba lesi-4, ivumela uhlengahlengiso lonyango oluguqukayo.

Ukuqukumbela

Ngo-2026, i-landscape ye inqanaba lomhlaza wesibindi 4 unyango e China iye yafumana utshintsho olunzulu. Zimnkile iintsuku apho ukuxilongwa kwakuthetha ukhathalelo olukhawulezileyo lwehospice. Namhlanje, i-arsenal eyomeleleyo yonyango-kubandakanya indibaniselwano yenoveli ye-TKI-immunotherapy, impumelelo yasekhaya efana ne-Finotonlimab, kunye nezilingo ezibukhali ze-CAR-T-zinika ithemba lokwenyani lokusinda okwandisiweyo kunye nokuphucula umgangatho wobomi.

Ngamaxesha aphakathi okusinda adlulela ngaphaya kweminyaka emibini kunye neqela elikhulayo labasindi bexesha elide, imbonakalo iqaqambile kunangaphambili. Ngelixa imiceli mngeni emalunga neendleko kunye nofikelelo isaqhubeka, iinzame ezimanyeneyo zenkqubo yokhathalelo lwempilo yaseTshayina ukudibanisa inguqulelo nokufikeleleka zenza olu nyango lusindisa ubomi lufikeleleke ngakumbi.

Kwizigulane kunye neentsapho, eyona nto iphambili ixhomekeke ekufuneni ukhathalelo kumaziko akhethekileyo, ukuhlola zonke iinketho ezikhoyo kuquka izilingo zonyango, kunye nokugcina unxibelelwano oluvulekileyo nababoneleli bezempilo. Uhambo olunenqanaba lesi-4 lomhlaza wesibindi luntsonkothile, kodwa ngenkqubela phambili ka-2026, luhambo oluzaliswe ngamathuba angazange abonwe ngaphambili.